Material News
No news available.
Material News archive
2023
2022
2021
Ad Hoc News PDF archive
2020 (since April 2020)
2020 (until April 2020)
- 20200323_Ad_hoc_withdrawal_subscribtion_CB_EN_final.pdf
- 20200303_Ad_hoc_binding_term-sheet_Maruho_EN_final.pdf
- 20200313_Ad_hoc_non-binding_term_sheet_Poland_EN_final.pdf
- 20200312_Ad_hoc_extension_subscription_period_CB_EN_final.pdf
- 20200226_Ad_hoc_convertible_bond_EN_final.pdf
- 20200110_Ad_hoc_Prelim_results_Q4_EN_final.pdf
- 20200420_Ad_hoc_Maruho_license_agreement_EN_final.pdf
- 20200416_Ad_hoc_resolution_for_ordinary_capital_increase_AGM_EN_final.pdf
- Publication pursuant to Section 111c AktG 11.03.2020
2018
- 20181010_Adhoc Meldung_Prelim Q3_EN_final.pdf (175 KB)
- 20180412 ad hoc_Q1results_EN.pdf (43 KB)
- 20180305_ad hoc_Daylight approval_EN.pdf (45 KB)
- ad_hoc_20180213_EN_KE_results_final.pdf (43 KB)
- ad_hoc_20180209_EN_KE_price.pdf (58 KB)
- ad_hoc_20180131_EN_KE_price_range.pdf (44 KB)
- ad_hoc_20180129_EN_daylight.pdf (43 KB)
- 20180129 Ad-hoc KE_EN.pdf (37 KB)
- ad_hoc_20180123_EN_final.pdf (47 KB)
- ad_hoc_nasdaq_EN_final.pdf (43 KB)
2017
- 01/24/2017 Ad-hoc: Bond Issue: 49.990 subordinate convertible debenture fully placed (79 KB)
- 01/30/2017 Ad-hoc: European Commission extends Ameluz® approval to basal cell carcinoma (33 KB)
- 02/06/2017 Ad-hoc: Biofrontera Reports Positive Phase III Results for Ameluz® in Combination with Daylight-PDT (82 KB)
- 05/19/2017 Ad-hoc: Biofrontera enters into finance contract with European Investmentbank (154 KB)
- 07/28/2017 Ad-hoc: Biofrontera AG: Warrant bond 2009/2017 will be repaid early (33 KB)
- 11/14/2017 Ad-hoc: Biofrontera adjusts revenues and earnings forecast for the financial year 2017 (64 KB)
2016
- 01/04/2016 Ad-hoc: RNS release: Total Voting Rights (75 KB)
- 01/20/2016 Ad-hoc: RNS release: Notice of Cancellation from Trading on AIM (169 KB)
- 01/28/2016 Ad-hoc: Biofrontera‘s Ameluz® achieves excellent results in clinical study for basal cell carcinoma (218 KB)
- 02/16/2016 Ad-hoc: Biofrontera AG resolves on capital increase (79 KB)
- 03/24/2016 Ad-hoc: Biofrontera AG anticipates capital increase (78 KB)
- 03/29/2016 Ad-hoc: Biofrontera AG resolves on capital increase (93 KB)
- 04/18/2016 Ad-hoc: Capital increase several times oversubscribed (36 KB)
- 05/11/2016 Ad-hoc: FDA grants approval for Ameluz® in the USA (79 KB)
- 07/13/2016 Ad-hoc: Biofrontera AG and Maruho Initiate Joint Project to Explore Development Opportunities (92 KB)
- 10/31/2016 Ad-hoc: Biofrontera AG resolves on capital increase and issue of convertible bonds (79 KB)
- 11/17/2016 Ad-hoc: Capital Increase: 5,012,950 New Shares fully placed (33 KB)
- 11/24/2016 Ad-hoc: Bond Issue: 49,990 subordinate convertible debentures fully placed (33 KB)
- 12/23/2016 Ad-hoc: Biofrontera AG resolves on issue of convertible bonds (81 KB)
2015
- 04/09/2015 Ad-hoc: RNS release: Final Results 2014 (479 KB)
- 04/23/2015 Ad-hoc: Biofrontera AG – Biofrontera AG resolves on capital increase (121 KB)
- 04/23/2015 Ad-hoc: RNS release: Open Offer and Private Placement (77 KB)
- 04/27/2015 Ad-hoc: RNS Release: Further re: Subscription Offer and Private Placement (275 KB)
- 04/27/2015 Ad-hoc: Subscription offer from the capital increase resolved upon on 04/23/2015 from authorized capital (178 KB)
- 05/27/2015 Ad-hoc: Biofrontera AG – 1,377,272 shares placed in capital increase (78 KB)
- 07/16/2015 Ad-hoc: RNS release: Notice of Annual General Meeting (94 KB)
- 08/13/2015 Ad-hoc: RNS release: Half Year Results - Good progress made in first half of 2015 (274 KB)
- 09/12/2015 Ad-hoc: FDA accepts filing of Ameluz® and BF-RhodoLED® application (119 KB)
- 10/27/2015 Ad-hoc: Biofrontera AG – Biofrontera AG resolves on capital increase (37 KB)
- 10/27/2015 Ad-hoc: RNS release: Open Offer and Private Placement (22 KB)
- 10/28/2015 Ad-hoc: RNS release: Further re - Open Offer and Private Placement (446 KB)
- 11/05/2015 Ad-hoc: Biofrontera AG – subscription price for New Shares from ongoing capital increase determined (121 KB)
- 11/23/2015 Ad-hoc: Biofrontera AG – 1.9 mio shares placed in capital increase (139 KB)
- 12/10/2015 RNS release: Issue of equity and total voting rights (76 KB)